Osteoporosis: Drugs
(asked on 23rd October 2014) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years.
Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.
Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:
6.6 Drugs affecting bone metabolism
9.5.1.1 Calcium supplements
9.6 Vitamins (colecalciferol and ergocalciferol only)
Cost of drugs for the treatment of osteoporosis, England1 | ||||||||||
Drug Name2 | Primary Care (£ million) | Secondary Care (£ million) | ||||||||
Year | 2009 | 2010 | 2011 | 2012 | 2013 | 2009 | 2010 | 2011 | 2012 | 2013 |
Alendronic Acid | 14.0 | 12.4 | 10.8 | 9.7 | 8.9 | 0.8 | 0.6 | 0.5 | 0.5 | 0.4 |
Alendronic Acid and Colecalciferol | 1.4 | 1.2 | 0.9 | 0.7 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Calcitonin (Salmon) | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 |
Calcium | 4.2 | 4.7 | 4.5 | 3.7 | 3.3 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 |
Calcium and Colecalciferol | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.2 | 2.2 | 2.1 | 2.2 | 2.3 |
Clodronic Acid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.9 | 2.4 | 1.6 | 1.2 | 0.9 |
Colecalciferol | 42.4 | 48.3 | 58.5 | 67.6 | 75.0 | 0.0 | 0.0 | 0.0 | 0.4 | 1.2 |
Denosumab | 0.0 | 0.0 | 0.2 | 0.8 | 1.9 | 0.0 | 0.1 | 0.9 | 2.3 | 9.9 |
Disodium Etidronate | 1.3 | 1.0 | 0.8 | 0.6 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Ergocalciferol | 4.3 | 7.8 | 8.0 | 7.0 | 6.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 |
Ibandronic Acid | 12.1 | 12.1 | 11.4 | 10.6 | 4.7 | 2.1 | 2.0 | 1.8 | 1.5 | 0.9 |
Pamidronic Acid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.6 | 9.1 | 9.4 | 9.4 | 8.7 |
Risedronate Sodium and Risedronate Acid | 27.9 | 22.9 | 11.6 | 2.4 | 2.0 | 0.8 | 0.6 | 0.3 | 0.1 | 0.1 |
Sodium Clodronate | 7.8 | 7.2 | 6.3 | 5.5 | 4.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Strontium Ranelate | 7.0 | 7.8 | 9.0 | 9.2 | 7.3 | 0.6 | 0.6 | 0.6 | 0.5 | 0.2 |
Teriparatide | 0.3 | 0.4 | 0.4 | 0.5 | 0.6 | 2.7 | 2.8 | 2.7 | 3.1 | 3.2 |
Zoledronic Acid | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 16.7 | 18.0 | 20.9 | 23.7 | 25.7 |
Other Calcium Supplement Preps | 0.5 | 0.6 | 0.6 | 0.5 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Other drugs3 | 0.2 | 0.1 | 0.1 | 0.0 | 0.0 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 |
TOTAL | 123.8 | 126.8 | 123.4 | 119.1 | 115.4 | 39.6 | 39.6 | 42.3 | 46.2 | 55.0 |
1 Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.
2 The patent for some of these drugs may have expired during this period.
3 “Other drugs” includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.
Source:
Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)
Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)
Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.